Table 1.
Effects of either central (intracerebroventricular) or peripheral (intraperitoneal) administration of vehicle and the CBl cannabinoid receptor antagonist SR141716A on motor behaviors measured in the open field
| Crossings | Rearings | Time spent grooming | |
|---|---|---|---|
| Vehicle, (intracerebroventricular) | 160.6 ± 20.9 | 46.0 ± 6.2 | 27.8 ± 8.5 |
| SR141716A, (5 μg/5 μl, i.c.v.) | 120.8 ± 18 | 20.2 ± 5.9* | 84.5 ± 14.5* |
| Vehicle, (intraperitoneal) | 143.3 ± 0.7 | 30.9 ± 4.1 | 8.8 ± 4.2 |
| SR141716A, (3 mg/kg, i.p.) | 156.9 ± 24.7 | 9.0 ± 2.7* | 25.4 ± 10.6* |
-
↵* p < 0.05; Newman–Keuls.
